DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer

Not Applicable

Recruiting

Conditions: Fibroblast Activation Protein Inhibitor
Malignant Tumor
Positron Emission Tomography

Interventions: Diagnostic Test: 68Ga-TCR-FAPI PET/CT

First Posted Date: 2023-10-16

Last Posted Date: 2023-10-23

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06084767

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, China

A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: c610 injection

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 62

Registration Number: NCT06082570

A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer

Phase 3

Recruiting

Conditions: Thyroid Cancer
Recurrence

Interventions: Procedure: prophylactic central neck dissection

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 1199

Registration Number: NCT06082180

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

Phase 1

Not yet recruiting

Conditions: Malignant Solid Tumors

Interventions: Drug: T60c injection

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 62

Registration Number: NCT06082557

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Muscle Invasive Bladder Carcinoma

Interventions: Drug: RC48-ADC
Drug: AK104

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT06074484

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

NV-001 in the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Malignant Neoplasm

Interventions: Biological: NV-001

First Posted Date: 2023-09-25

Last Posted Date: 2025-02-12

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT06051760

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis

Not Applicable

Conditions: Lymph Node Metastasis
Cancer of Rectum and Anus
Oxaliplatin
Intestinal Neoplasms
Gastrointestinal Neoplasms
Rectal Diseases
Rectal Neoplasms

Interventions: Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection

First Posted Date: 2023-09-21

Last Posted Date: 2023-11-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 180

Registration Number: NCT06048146

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, China

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Phase 1

Recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: Surufatinib Combined With Temozolomide and S-1

First Posted Date: 2023-09-14

Last Posted Date: 2024-10-01

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT06038461

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Active, not recruiting

Conditions: Gastric Cancer Stage IV
First-line
Chemotherapy
Tislelizumab

First Posted Date: 2023-09-13

Last Posted Date: 2023-09-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06034964

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Applications of Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation

Not Applicable

Recruiting

Conditions: Fluorescence
Indocyanine Green
Rectal Cancer Surgery

Interventions: Device: Fluorescence laparoscopic system

First Posted Date: 2023-09-13

Last Posted Date: 2023-09-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT06033794

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy